Li Hongyu, Jia Yanfei, Wang Yunshan
Pharmazie. 2019 Jan 1;74(1):3-7. doi: 10.1691/ph.2019.8674.
Gastric cancer is a common malignancy with high mortality and limited therapeutic options. Hypoxia inducible factor-1 α (HIF-1α) is the key responser adapted to tumor hypoxia. Under hypoxia conditions, HIF-1α signaling is activated and responsible for cell biology associated with metabolism, inflammation, vascular homeostasis and tumorigenesis. Activation of HIF-1α signaling has been observed in a series of cancers including gastric cancer. Moreover, a variety of oncogene products may be induced by HIF-1α expression. Pharmacologic manipulation of HIF-1α may provide a novel therapeutic approach to gastric cancer. In this review, we summarize the recent information on HIF-1α in gastric cancer with special focus on the mechanism underlying HIF-1α signaling effects on proliferation, apoptosis, angiogenesis, EMT and drug-resistance of cancer cells, thereby predicting new therapeutic agents for better management of this malignancy.
胃癌是一种常见的恶性肿瘤，死亡率高且治疗选择有限。缺氧诱导因子-1α（HIF-1α）是适应肿瘤缺氧的关键应答因子。在缺氧条件下，HIF-1α信号被激活，并负责与代谢、炎症、血管稳态和肿瘤发生相关的细胞生物学过程。在包括胃癌在内的一系列癌症中都观察到了HIF-1α信号的激活。此外，多种癌基因产物可能由HIF-1α表达诱导产生。对HIF-1α进行药物调控可能为胃癌提供一种新的治疗方法。在这篇综述中，我们总结了关于胃癌中HIF-1α的最新信息，特别关注HIF-1α信号对癌细胞增殖、凋亡、血管生成、上皮-间质转化和耐药性影响的潜在机制，从而预测新的治疗药物，以更好地管理这种恶性肿瘤。
